Resource Logo
NLM AIDSLINE

Recombinant immunoblot assays for hepatitis C in human immunodeficiency virus type 1-infected US Navy personnel.




 

J Infect Dis. 1993 Mar;167(3):715-9. Unique Identifier : AIDSLINE

The prevalence of hepatitis A, B, C, and D viruses was studied in 467 military personnel with human immunodeficiency virus type 1 (HIV-1) infection. Antibody to hepatitis C virus (anti-HCV) by first-generation ELISA was found in 136 (29%). Of sera repeatedly reactive for anti-HCV by first-generation ELISA, two-antigen recombinant immunoblot assay (RIBA) was positive in 41 (32%) and four-antigen RIBA was positive in 55 (41%). Four-antigen RIBA was positive in 33 (30%) of the 109 with an OD on ELISA of < or = 2.0 compared with 22 (81%) of the 27 with an OD > 2.0 (P < .001). Anti-HCV detected by four-antigen RIBA was associated with increasing age, black or Hispanic race, and antibody to hepatitis B core antigen. When patients with hepatitis B surface antigen were excluded, elevated alanine aminotransferase was found in 5 (8%) of 63 with a negative RIBA and 13 (28%) of 47 with a positive RIBA (P = .006). While RIBA was negative in more than half of those with anti-HCV by ELISA, 55 (12%) of these HIV-1 infected personnel had anti-HCV detected by RIBA, which was associated with a strong reaction by ELISA, elevated liver enzymes, coinfection with hepatitis B, minority race, and older age.

Alanine Aminotransferase/BLOOD Analysis of Variance *AIDS-Related Opportunistic Infections Enzyme-Linked Immunosorbent Assay Female Hepatitis Antibodies/BLOOD Hepatitis B Surface Antigens/BLOOD Hepatitis C/COMPLICATIONS/DIAGNOSIS/*EPIDEMIOLOGY Hepatitis C Viruses/IMMUNOLOGY Hepatitis, Viral, Human/EPIDEMIOLOGY Human *HIV-1 Immunoblotting/METHODS Male *Military Personnel Naval Medicine Regression Analysis Sex Factors Support, U.S. Gov't, Non-P.H.S. Syphilis/COMPLICATIONS United States JOURNAL ARTICLE



 




Information in this article was accurate in June 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.